NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Vanda Pharmaceuticals Inc. VNDA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$216.1M
▲ 8.7% vs FY2024
EPS · FY25
$-3.74
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-50.9%
Net margin · FY25
-102.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 216.1M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 102 cents on every revenue dollar this year.
Per share
USD -3.74
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-50.9%
Return on equity, FY2025
ROE
Operating margin-70.0%
Net margin-102.0%
Return on assets-38.5%
Each USD of equity lost 51 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−5.3%
−2.7%
+7.0%
+12.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+7.7%
Change, 10 years+38.0%
The share count grew 8% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 488.9M
total assets, end of FY2025
Total assetsUSD 488.9M
EquityUSD 327.2M
CashUSD 84.9M
Current ratio2.39×
Equity funds 67% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.2
0.2
0.3
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
EBITDA $B
−0.2
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
Income tax $B
0.1
−0.0
0.0
0.0
0.0
0.0
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
0.0
·
Net income $B
−0.2
−0.0
0.0
0.0
0.0
0.0
0.1
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
EPS, diluted $
−3.74
−0.33
0.04
0.11
0.58
0.42
2.11
0.48
−0.35
−0.41
−0.94
0.55
−0.69
−1.01
−0.35
0.25
−1.33
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−50.9
−3.5
0.5
1.2
6.9
5.4
33.7
12.4
−11.9
−13.6
−27.1
19.7
−77.9
−131.9
−27.5
23.7
−155.7
Shares out B
0.06
0.06
0.06
0.06
0.06
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed